A Series C funding round has generated $34.4 million for Jena, Germany-based InflaRx. The firm will start two additional midstage studies for its humanized monoclonal antibody IFX-1, which is designed to prevent organ dysfunction and severe systemic inflammation in cardiac surgery patients.